{"groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) were screened to be randomized in sub-studies of this master protocol.","id":"FG000","title":"All Screened Participants"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"62"}],"type":"Screen Failed"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Completed screening but not randomized to sub study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"271"}],"comment":"All participants who were screened for eligibility.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"208"}],"comment":"All participants who passed screening and were randomized to sub-studies.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"63"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 271 participants started the overall study which includes all participants who were screened for eligibility prior to enrollment. 208 participants met eligibility criteria and were randomized in the sub-studies.","recruitmentDetails":"This master record includes data of screened participants for its sub-studies, 208887 Substudy 1 (NCT06160609), Substudy 2 (NCT07217119), Substudy 3 (NCT07084896), Substudy 4 (NCT06655818), Substudy 5 (NCT07217184), Substudy 6 (NCT07150091), Substudy 7 (NCT07150104) and only contains data collected during screening phase (Day -30 to Day 0). Results are presented separately for each sub study."}